Indivior PLC (LON:INDV – Get Free Report) traded down 19.5% on Thursday . The company traded as low as GBX 640 ($8.05) and last traded at GBX 698.90 ($8.79). 1,716,748 shares traded hands during trading, an increase of 144% from the average session volume of 704,709 shares. The stock had previously closed at GBX 868 ($10.92).
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 1,800 ($22.65) price objective on shares of Indivior in a research note on Tuesday, December 17th.
View Our Latest Research Report on Indivior
Indivior Stock Performance
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- Industrial Products Stocks Investing
- SoundHound AI Stock at a Crossroads—Is a Bottom in Sight?
- What is the Euro STOXX 50 Index?
- Hershey’s Sweet Comeback: Why Investors Are Taking Notice
- 3 Healthcare Dividend Stocks to Buy
- 3 Reasons Occidental Petroleum Will Gush Higher in 2025
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.